Economic evaluation

diabetic macular oedema

Ranibizumab may be cost-effective for diabetic macular oedema

Leave a Comment / Primary Care, Populations And Settings / By / , , ,

Blindness is one of the most serious microvascular complications of diabetes.  The most common cause is diabetic macular oedema (DME).  Current treatment with lasers is often unsuccessful. The new injectable drug ranibizumab, which works by selectively inhibiting vascular enothelial growth factor A, has been seen in the RESTORE trial to improve visual acuity and quality …

Ranibizumab may be cost-effective for diabetic macular oedema Read More »

Possible benefits of insulin pumps compared with multiple daily injections

Possible benefits of insulin pumps compared with multiple daily injections

Leave a Comment / Primary Care, Populations And Settings / By / , , ,

An appraisal of a 2010 systematic review of continuous subcutaneous insulin infusion (CSII, or insulin pumps) has been published in DARE. Research question: In diabetes, does CSII as compared with multiple daily injections (MDI), improve the clinical or cost-effectiveness of care? The review included both adults and children with type 1 or type 2 diabetes.  …

Possible benefits of insulin pumps compared with multiple daily injections Read More »

Diabetes care involving pharmacists to prevent CHD: a win-win?

Leave a Comment / Populations And Settings, Primary Care / By / , ,

Previous research has shown that pharmacist involvement in the management of type 2 diabetes can improve HbA1c as well as blood pressure and cholesterol. These models of care may be more costly to deliver, however, compared with conventional primary care. This economic evaluation looked at the cost-effectiveness of pharmacist management in preventing cardiovascular disease in …

Diabetes care involving pharmacists to prevent CHD: a win-win? Read More »